The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an ...

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal.

BioNTech is executing a fundamental strategic realignment, moving decisively away from its pandemic-related business toward an intensified focus on cancer medicine. The company is bolstering its ...

MAINZ, Germany, November 4, 2024-- BioNTech SE today reported financial results for the three and nine months ended September 30, 2024 and provided an update on its corporate progress. Ugur Sahin ...

The intervention being tested is BNT323/DB-1303, an investigational drug administered via intravenous infusion. It is compared against standard chemotherapy options, doxorubicin or paclitaxel, chosen ...

BioNTech SE is currently sponsoring a Phase II clinical study titled A Phase II, Multisite, Open-label, Single Arm Trial of BNT327 in Combination With Docetaxel in Second-line Stage IV Non-small Cell ...

The top executives running the health care industry’s blue-chip companies amassed generational wealth in 2024, even as many ...

Pfizer and BioNTech are planning to ask the Food and Drug Administration to authorize a second COVID-19 booster shot for people age 65 and older.

BioNTech responded in a statement that its work was original. Moderna has also been sued for patent infringement in the United States and has an ongoing dispute with the US National Institutes of ...

Moderna is suing fellow vaccine developers Pfizer and its German partner BioNTech, accusing it of infringing on patents related to mRNA technology used in their COVID-19 vaccine, the company ...

Moderna is suing Pfizer and BioNTech for infringing patents central to Moderna's mRNA technology platform used to develop the COVID vaccine, the company said in a press release Friday. A widely ...